Eli Lilly and Company

LLY

New York Stock Exchange. Currency in USD

357.78 -2.09 ( -0.58% )

Real time prices: December 19

Market Cap.
339.95B
Beta (5Y monthly)
0.35
Price/Earnings
44.58
EPS (TTM)
8.34
Forward Dividend
3.92 (1.08%)
Ex-Dividend Date
Feb 14, 2023
Volume
2.65M
1y Target Est.
384.60
Day's Range
354.61
-
359.70
52 Week's Range
231.87
-
375.25

Historical Summary

Performance
EPS growth
Share Buybacks

About Eli Lilly and Company

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.lilly.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
956.59M
Employees
35000
Address
Lilly Corporate Center, Indianapolis, IN, United States, 46285
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest news

This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots
This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots

A strategy of holding stocks that have been on an upswing has outperformed the S&P...
By MarketWatch - 6 weeks ago

Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?
Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?

AbbVie's valuation, in particular, makes it a potentially strong candidate for 2023, while Eli Lilly's...
By Zacks Investment Research - 7 weeks ago

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based...
By Zacks Investment Research - 7 weeks ago

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2022 Update
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2022 Update

Stanley Druckenmiller’s 13F portfolio value increased from $1.38B to $1.76B this quarter. Read more to...
By Seeking Alpha - 7 weeks ago

2 Dividend Stocks That Could See Big Rate Increases Next Year
2 Dividend Stocks That Could See Big Rate Increases Next Year

Both of these businesses are in good financial shape and can afford to boost their...
By The Motley Fool - 7 weeks ago

Carnival To Rally Over 36%? Here Are 10 Other Price Target Changes For Thursday
Carnival To Rally Over 36%? Here Are 10 Other Price Target Changes For Thursday

Barclays raised Carnival Corporation (NYSE: CCL) price target from $10 to $12. . Barclays analyst...
By Benzinga - 7 weeks ago

This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots
This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots

A strategy of holding stocks that have been on an upswing has outperformed the S&P...
By MarketWatch - 7 weeks ago

This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots
This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots

A strategy of holding stocks that have been on an upswing has outperformed the S&P...
By MarketWatch - 7 weeks ago